Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IMImmutep Limited logo

Immutep Limited (IMMP)

NASDAQ · Currency in USD
$3.20 ▲ +0.03 (+0.95%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.20 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.17
Open
$3.21
Day's Range
$3.10 – $3.24
52 Week Range
$3.06 – $70.60
Volume
7,898
Avg. Volume
426,823
Market Cap
$23.58M
Beta (5Y Monthly)
2.31
PE Ratio (TTM)
--
EPS (TTM)
-$0.54
Earnings Date
Feb 25, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.25

Profile: Immutep Limited

Sector
Healthcare
Industry
Biotechnology
Full-time employees
53
CEO
Marc Voigt

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

Earnings

Next report: Thu, Feb 25, 2027
EPS estimate -$1.45 · Revenue est. $1.43M
DateEst.Actual
Aug 30, 2026-$0.52-$3.11Miss
Feb 24, 2026-$0.20-$0.22Miss
Aug 29, 2025-$3.72-$3.72Beat
Feb 26, 2025-$0.14-$0.10Beat
Aug 29, 2024-$0.13-$0.12Beat
Apr 29, 2024-$2.50-$2.41Beat

Analyst view

Consensus price target
$4.25 ▲ +32.8%
Range $3.50 – $5.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on IMMP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.